Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 2/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 4/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21082997 | 0.91 | ANO1 (0.35) | SHMT1SHMT2P2RX7MEN1ALDH1A1 | |
| SCHEMBL19838164 | 0.82 | SHMT1 (0.41) | SHMT1SHMT2FABP4FABP5P2RX7 | |
| SCHEMBL19838161 | 0.81 | SHMT1 (0.41) | SHMT1SHMT2FABP4FABP5P2RX7 | |
| SCHEMBL7958051 | 0.77 | ALDH1A1 (0.39) | SHMT1SHMT2LPAR1ALDH1A1 | |
| SCHEMBL19838513 | 0.77 | P2RX7 (0.35) | SHMT1SHMT2P2RX7MEN1ALDH1A1 | |
| SCHEMBL12738955 | 0.76 | ANO1 (0.37) | SHMT1SHMT2P2RX7ALDH1A1GAA | |
| SCHEMBL23326474 | 0.76 | SHMT1 (0.37) | SHMT1SHMT2FABP4FABP5P2RX7 | |
| SCHEMBL21469463 | 0.76 | MAPK1 (0.32) | SHMT1SHMT2P2RX7 | |
| SCHEMBL7949624 | 0.76 | LPAR1 (0.39) | SHMT1SHMT2LPAR1ALDH1A1 | |
| SCHEMBL7960775 | 0.76 | LPAR1 (0.39) | SHMT1SHMT2LPAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294539-A1 | PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-05 | — | — | US | disclosed |
| EP-3494109-A1 | METHOD FOR PRODUCING SPIROKETAL-SUBSTITUTED CYCLIC KETOENOLS | Bayer CropScience Aktiengesellschaft (DE) | 2019-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294539-A1 | PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS | BCAT1, BCAT2, BCKDK | SHMT1 1468/4885SHMT2 1983/4885FABP4 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.